A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of multiple oral doses of tasimelteon and matching placebo in travelers with Jet Lag Disorder

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of multiple oral doses of tasimelteon and matching placebo in travelers with Jet Lag Disorder

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Circadian rhythm sleep disorders; Jet lag
  • Focus Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2016 Status changed from planning to recruiting.
    • 10 Feb 2016 According to a Vanda Pharmaceuticals media release, this study is expected to begin in the second half of 2016.
    • 03 Nov 2015 According to a Vanda Pharmaceuticals media release, this study is expected to begin in the first quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top